Continuing Medical Education
FELLOW’S FORUM
The Fellows’ Forum is a scientific meeting envisioned to be a venue for academic interchange among subspecialists and related fields constituting the multidisciplinary team involved in the care of women with high risk pregnancies. The forum will be held regularly on a monthly interval , 5 times a year, from January to October. It will be hosted by institutions with an accredited Maternal-Fetal Medicine fellowship training program on a rotation basis. The host institution will present a case or case series admitted in its hospital.
PSMFM Mondays: 1st Fellows Forum
Host Hospital: Rizal Medical Center
Date: January 15, 2024
Theme: Pregnancy Associated Myocardial Infarction
Venue: B Hotel, Scout Rallos, Quezon City
Total in-person attendance: 84
Total virtual attendance: 205
Dr. Juli Denise V. Cuarto, a senior fellow-in-training at Rizal Medical Center, presented a case of a 38-year-old multigravida who exhibited chest pains, difficulty breathing, and weakness for two days. The 12-lead ECG revealed T-wave inversion, global ischemia, and elevated Troponin I. She emphasized that Acute Coronary Syndrome disproportionately affects women during pregnancy, underscoring the critical importance of early recognition for optimal management, particularly in the late third trimester and early postpartum. The leading causes include spontaneous artery dissection, normal coronary arteries, coronary thrombosis, coronary embolism, coronary vasospasm, and atherosclerotic CAD. The diagnosis of Pregnancy Associated Myocardial Infarction relies on anginal symptoms, ECG changes, and elevated cardiac markers, mirroring the diagnostic principles applied to non-pregnant individuals. Women may also present with typical or atypical anginal symptoms. ECG changes during a normal pregnancy encompass left axis deviation, T-wave inversion ranging from 0.5 to 1 mm, and Q waves.
Furthermore, Dr. Cuarto, along with invited experts in Internal Medicine-Adult Cardiology and Interventional Cardiology, namely Dr. Marian Joy A. Lopez and Dr. Anna Francesca S. Abarquez, elucidated the fundamental principles in the management of pregnancy-associated myocardial infarction.
In the context of pregnancy-associated Acute Coronary Syndrome, coronary angiography stands as the diagnostic and therapeutic gold standard. For patients with Non-ST Elevation MI or hemodynamically non-ST elevation MI, angiography should be considered, irrespective of pregnancy status.
A multidisciplinary cardio-obstetrics team should guide decisions regarding the timing of delivery in patients who have experienced pregnancy-associated ACS. Without clinical indications for urgent or emergent delivery, the prevailing practice guidelines and expert consensus advocate delaying delivery until at least two weeks following PAMI to mitigate maternal complications.
Dr. Anita Matilda F. Poblete, a maternal-fetal medicine expert, underscored the pivotal aspects of the perinatal management of women afflicted with Preeclampsia complicated by suspected myocardial infarction during the antepartum period.
The discourse also underscored that a majority of women who undergo delivery after PAMI are subjected to monitoring in an intensive care setting due to the potential presentation of new-onset ACS during the postpartum period. Importantly, mortality associated with myocardial infarction appears to be less prevalent during the postpartum period compared to during pregnancy.
Regarding subsequent pregnancies, it is recommended to consider conception in the absence of clinical evidence of persistent left ventricular dysfunction or ischemia, with a proposed delay of 12 months following MI. In cases where the previous MI was attributed to SCAD, the consensus recommends against future pregnancy, acknowledging the potential need for individualized counseling.
PSMFM Mondays: 2nd Fellows Forum
Host Hospital: East Avenue Medical Center
Date: April 15, 2024
Theme: CONNed – A Case of Primary Aldosteronism in Pregnancy
Venue: B Hotel, Scout Rallos, Quezon City
Total in-person attendance: 76
Total virtual attendance: 145
Dr. Andrew Buenviaje, fellow-in-training, presented a detailed summary of the case of a 33-year-old primigravid diagnosed with primary aldosteronism secondary to an aldosterone-secreting cortical adenoma. The presentation covered different algorithms in diagnosis and management, along with evidence-based guidelines, and emphasized clinical correlation. There was a comprehensive discussion on secondary hypertension in pregnancy caused by an aldosterone-secreting cortical adenoma complicated by severe preeclampsia, leading to the need for preterm delivery.
Dr. Ronald Chua, from an Endocrinologist point-of-view, discussed the clinical course, including different screening and confirmatory tests and their application to pregnant and non-pregnant women. The presentation also delved into the medical management of primary aldosteronism, particularly for patients who are not surgical candidates or do not consent to surgery.
Dr. Dean Xyrus Seares, from a Urologist point-of-view, provided a comprehensive overview of the retroperitoneoscopic laparoscopy procedure.
Dr. Paula Christi Tolentino-Orlina, from a Maternal-Fetal Medicine specialist point-of-view, offered valuable insights on primary aldosteronism in pregnancy, addressing various issues associated with the condition, including the reciprocal effects of pregnancy on hyperaldosteronism and vice versa. Dr. Orlina succinctly consolidated all topics discussed and highlighted several key learning points.
Lastly, Dr. Grace Lynn Estanislao, a senior fellow-in-training from The Medical City, presented and appraised a journal entitled “Management and Outcome of Primary Aldosteronism in Pregnancy: A Systematic Review.”
PSMFM Mondays: 3rd Fellows Forum
Host Hospital: Bicol Medical Center
Date: June 10, 2024
Theme: A Case of Severe Mitral Stenosis in Pregnancy
Venue: B Hotel, Scout Rallos, Quezon City
Total in-person attendance: 80
Total virtual attendance: 138
Dr. Carole Ann T. Santy-Roco, fellow-in-training, delivered a comprehensive analysis of a 25-year-old patient diagnosed with Rheumatic Heart Disease and Mitral Stenosis, who was admitted at 23-24 weeks age of gestation due to complications related to pulmonary congestion. She emphasized that the assessment of the risk of pregnancy in women with known cardiovascular disease should be individualized and ideally performed before pregnancy, including adjustments to medication, such as suspending contraindicated drugs and introducing alternatives. She presented several scores to stratify the risk of cardiovascular complications in pregnancy, with the most commonly used being the Cardiac Disease in Pregnancy (CARPREG) risk score. The European Society of Cardiology (ESC) guidelines for assessing the risk of these women were highlighted as an essential tool for risk assessment, emphasizing the cardiovascular complication risk based on the World Health Organization (WHO) classification.
Dr. Theo Jay T. Santy III, a seasoned Interventional Cardiologist, discussed the effects of Valve Stenosis on Pregnancy, mentioning that Mitral Stenosis is the most common valve disease in women of childbearing age, with 90% of cases being of rheumatic origin. He thoroughly explained the hemodynamic changes associated with pregnancy and its effect on the existing cardiac pathology, putting the patient at risk for common complications such as arrhythmias (most often atrial fibrillation [AF]) and pulmonary embolism. Treatment options for symptomatic patients may include beta blockers to prolong ventricular filling time and reduce left atrial pressure and, if necessary, diuretics to relieve congestion. Anticoagulation is indicated in atrial fibrillation, atrial thrombi, or a history of thromboembolism. Percutaneous mitral commissurotomy should be a choice only when, despite medical treatment, the patient remains in NYHA class III/IV, preferably not until after 20 weeks gestation. Cardiac surgery should be reserved for life-threatening situations in which all other measures have failed.
Dr. Olivia Jane Chua-Fernandez, an expert in maternal-fetal medicine, delivered a comprehensive presentation focusing on antenatal surveillance, timing and mode of delivery, anesthesia, and postpartum considerations. In summary, she explained that the type of delivery should be decided and scheduled by a multidisciplinary team. The preferred mode of delivery is vaginal, with a delivery plan individualized to the patient, her disease, and her hemodynamic profile. Cesarean section, although controversial, is indicated for patients with conditions in WHO risk group IV, under oral anticoagulation in preterm labor, with decompensated heart failure (HF), or for obstetric indications.
PSMFM Mondays: 4th Fellows Forum
Host Hospital: St. Luke’s Medical Center – Quezon City
Date: July 8, 2024
Theme: All OUT ON PAS: Diagnosis and Management Strategies on Placenta Accreta Spectrum
Venue: B Hotel, Scout Rallos, Quezon City
Total in-person attendance: 80
Total virtual attendance: 390
Dr. Maria Lourdes Felise Gonzales, fellow-in-training, extensively deliberated on three cases of placenta accreta spectrum disorders. The initial case was diagnosed with placenta percreta both antenatally and through histopathologic examination. The second case was diagnosed with placenta increta, both antenatally and based on histopathologic diagnosis. The final case was diagnosed with placenta accreta, both antenatally and through histopathologic diagnosis. High clinical suspicion for PAS is warranted in patients with a previous cesarean delivery and placenta previa in the current pregnancy. Other notable risk factors for PA include in vitro fertilization, multifetal pregnancy, prior uterine procedures, and advanced maternal age. Timely ultrasound evaluations for high-risk individuals are pivotal for swift diagnosis and are typically conducted at specified intervals: 18-20, 28-30, and 32-34 weeks of gestational age. This is particularly important for optimizing delivery planning for asymptomatic patients. The predominant strategy regarding PAS is to retain the placenta in situ and perform peripartum cardiomyopathy at delivery, with a deliberate avoidance of attempts to remove the placenta to mitigate uncontrolled major obstetric hemorrhage. Ultimately, management decisions are influenced by the extent of villous invasion, presenting symptoms, and the availability of local expertise. Therefore, it is recommended that a tertiary care facility adopt a multidisciplinary approach, involving obstetricians, radiologists, maternal-fetal medicine specialists, gynecologic oncologists, and other medical practitioners, to successfully manage PAS cases.
Dr. Katherine B. Saniel, a maternal-fetal medicine specialist, underscored the pivotal role of ultrasound in the antenatal diagnosis of PAS. She highlighted specific ultrasonographic markers in the first, late second, and third trimesters, as well as the diagnosis of cesarean scar pregnancy as an early manifestation of PAS.
Radiologist and body imaging specialist, Dr. Joyce D. Komiya, emphasized the crucial role of MRI in the diagnosis of PAS. She highlighted that optimal MRI evaluation occurs between 24-30 weeks of gestational age, and stressed that beyond 30 weeks of gestation, MRI should not be discounted, especially when there is a potential for bladder wall involvement.
Dr. Leo Francis N. Aquiizan, a gynecologic oncologist, comprehensively expounded on the different surgical management options of PAS, especially focusing on traditional and conservative management. Cesarean hysterectomy was highlighted as the gold standard, and options for conservative management in cases of unexpected PAS or for preservation of fertility were thoroughly discussed.
A journal presentation was done by Dr. Alaine R. Villanueva, fellow-in-training.
PSMFM Mondays: 5th Fellows Forum
Host Hospital: Jose R. Reyes Memorial Medical Center
Date: August 12, 2024
Theme: Challenges And Insights In The Diagnosis And Treatment Of Fetal Hydrops
Venue: B Hotel, Scout Rallos, Quezon City
Total in-person attendance: 80
Total virtual attendance: 271
Dr. Rhoselle P. Miguel, a fellow-in-, presented a case involving a pregnant patient with hydrops fetalis, hydramnios, and paroxysmal supraventricular tachycardia. The initial trimester screening, including the assessment of nuchal translucency at 12 weeks of gestation, indicated normal results. However, at 21 weeks, a fetal ultrasound revealed indications of hydrops fetalis, alongside normal amniotic fluid volume. Additionally, the mother exhibited hypertension at a reading of 150/100. Subsequent to this, a repeat scan at the 28th week displayed hydrops fetalis and anhydramnios, coupled with the diagnosis of right renal agenesis. Further imaging at 29 weeks and 3 days gestation confirmed the absence of the right kidney and the presence of a hypoplastic left kidney. Her subsequent delivery resulted in the birth of a live baby girl through normal spontaneous delivery, who regrettably expired after 2 minutes of life.
Dr. Ma. Victoria V. Torres, a maternal-fetal medicine specialist, and Dr. Maria Melanie Liberty B. Alcausin, the director of the institute of human genetics at NIH, provided in depth and valuable insights regarding the case.
Fetal hydrops involves an accumulation of fluid in two or more fetal extravascular compartments and may be associated with polyhydramnios or placentomegaly. It has two types: immune and non-immune. The patient and her husband have O+ blood types, so the case is classified as non-immune hydrops. The patient and her husband exhibit microcytic and hypochromic red blood cell indices. While the patient’s hemoglobin electrophoresis returned normal, additional consideration is warranted for the possibility of alpha thalassemia causing the hydrops fetalis. The work-up for non-immune hydrops fetalis encompasses a detailed maternal history and fetal echocardiogram. If the echocardiogram is unremarkable with no arrhythmia, the next step is a MCA Doppler to rule out fetal anemia. If the MCA PSV is >/= 1.5 MoM, amniocentesis for fetal karyotyping and PCR for CMV, parvovirus, and toxoplasmosis should be considered. Fetal blood sampling may also be indicated with or without intrauterine transfusion. Counseling is imperative, both antenatally and postpartum, focusing on the underlying etiology, prognosis, and options for fetal therapy, including risks and benefits of treatment versus no treatment, as well as the prognosis. The prognosis hinges on the underlying etiology, gestational age at detection of fetal hydrops and delivery, APGAR scores, the extent of resuscitation, and the need for post-delivery transport. Early diagnosis of hydrops fetalis before 24 weeks carries a worse prognosis, usually associated with aneuploidy. Even without chromosomal abnormalities, survival chances are less than 50%. In this specific case, the patient was counseled with a poor prognosis due to the early onset of hydrops fetalis at 21 weeks of gestation, coupled with congenital anomalies. During postpartum counseling, it is important to emphasize the need to search for the underlying cause of the hydrops. If genetically related, the patient should be informed about the risk of recurrence in subsequent pregnancies, and risk assessment and monitoring should commence early in the first trimester.
A journal presentation was done by Dr. Jennifer Mary Joy V. Chiu, a fellow-in-training.
Special Interest Groups
PSMFM Special Interest Groups (SIGs) are composed of members who share mutual and common goals and interests in the exploration and advancement of specific areas of knowledge and expertise in Maternal Fetal Medicine.
Hypertension in Pregnancy
ELIZABETH SUPELANA, MD
TRINILISA BAGALSO, MD
LINDA LUISA YANDOC, MD
CARMEN ADELA PEREZ, MD
CECILE STA. ANA, MD
GAYLINEL BONGYAD-SAN PEDRO, MD
JULIETA VILLANUEVA, MD
CATHERINE JOIE CARELLE-ONG, MD
ALEJANDRA KAREN TOLEDO, MD
ZARAH CHARISSA MAGNAYE-AGUALADA, MD
JOSEPHINE SANCHEZ, MD
CATHERINE BARBOSA-MACARAIG, MD
MAYNILA DOMINGO, MD
LOIDA MICHELLE ONG, MD
WENDY NICANOR, MD
ALPHA MONTAOS, MD
MARIA THERESA LOPEZ, MD
ZARINAH GONZAGA, MD
SUSAN NAGTALON, MD
WALFRIDO SUMPAICO, MD
JOSEPH OLIVAR, MD
CARMELA MADRIGAL-DY, MD
JOSEPH CARL MACALINTAL, MD
MARJORIE SANTOS, MD
EBBY EUNIKA REBUGIO, MD
JAY VEE LYNE INIGO, MD
KRISTINA DOSDOS, MD
RICHARD JORDIAS, MD
Committee Chair:
Marjorie I. Santos, MD
VISION
To achieve universal first trimester screening for preeclampsia in the Philippines by 2030
MISSION
Our mission is to decrease maternal and perinatal morbidity and mortality by raising awareness of hypertensive disorders of pregnancy which will lead to the implementation of universal first trimester screening to prevent preeclampsia in high-risk pregnancies.
Preterm Labor
EMERSON TAN, MD
MA. GEMMA DATU FULGADO, MD
VANESSA MARIE LIM, MD
VICAR ONG, MD
ANA MARIE MADAMBA-BURGOS, MD
ZARAH CHARISSA MAGNAYE-AGUALADA, MD
CHRISTINE AGUILAR, MD
CATHERINE HUI TIIN LIM, MD
CATHERINE BARBOSA-MACARAIG, MD
VALERIE GAIL BAILON, MD
MAYNILA DOMINGO, MD
EDELIZA ELVAMBUENA-AMORIN, MD
KAREN TY-TORREDES, MD
MANBEE GENE GRANADA, MD
MAY HIPOLITO, MD
MA. CRISTINA CRISOLOGO, MD
NERISSA GRACIA NANO-DEGUZMAN, MD
IRENE QUINIO, MD
MARIA ESTRELLA FLORES, MD
ALDA GENE TREMOR, MD
MARIA ROSARIO CHENG, MD
ROSEMARIE QUILALA, MD
RINA RAMIRO, MD
ALEJANDRA KAREN Y. TOLEDO, MD
ALPHA MONTAOS, MD
ELIZABETH SUPELANA, MD
MA. SOCORRO ROGELAINE BRILLIANTES, MD
SHIERLY MAY DEL ROSARIO, MD
Committee Chair:
May N. Hipolito, MD
VISION
Our vision is to be the leading voice and advocate for the reduction in preterm births, and to work towards a future where every mother and baby receives the best possible care and support. We envision a Philippines where preterm labor is a rare occurrence, and where healthcare professionals have access to the resources, they need to identify those at risk, to intervene in preterm labor instances, and to prevent preterm births.
MISSION
Through our education efforts, we aim to increase awareness and knowledge of preterm labor, its risk factors, and strategies for prevention. Our service efforts aim to provide support and resources to healthcare professionals caring for women at risk for preterm labor by instilling early interventions that reduce the preterm birth risks and complications.
PPROM
CATHERINE JOIE CARELLE-ONG, MD
MARIA THERESA LOPEZ, MD
SUSAN NAGTALON, MD
Advanced Obstetric Ultrasound
TRINILISA BAGALSO, MD
EMERSON TAN, MD
MA CRESILDA PAZ SABULARCE, MD
ANA SY, MD
JOSEPH CARL MACALINTAL, MD
KATHRYN KRISTY BAUSTISTA, MD
MARLIZ ESCAÑO, MD
CARMEN ADELA PEREZ, MD
VANESSA MARIE LIM, MD
CECILE STA. ANA, MD
MARIA CARMINA SANTIAGO-OCAMPO, MD
VICAR ONG, MD
KRISTINA DOSDOS, MD
GLADIES, MD
AILEEN ONA-SUGUITAN, MD
JOSEPHINE SANCHEZ, MD
JOCELYN CENIZAL-BAMBALAN, MD
MARIE CATHELEEN SANTIAGO, MD
JOANNA PAULINE URSUA, MD
AMARYLLIS DIGNA YAZON, MD
ANNE VICTORIA MENDOZA, MD
JACEL ROSALES, MD
JAY VEE LYNE IÑIGO, MD
EBBY EUNIKA REBUGIO, MD
ZARINAH GONZAGA, MD
MAYCHIEL PEREZ, MD
CLARISSA VELAYO, MD
MILA IBAY, MD
YVONNE JOIE PALMA, MD
CARMELA MADRIGAL-DY, MD
ANGELITA TEOTICO, MD
LEAH SOCORRO RIVERA, MD
VALERIE GUINTO, MD
EMICIEL ALTA GIGANTE, MD
CHRISTINE AGUILAR, MD
BERLY BALITA, MD
CATHERINE BARBOSA-MACARAIG, MD
CATHERINE JOIE CARELLE ONG, MD
ELIZABETH SUPELANA, MD
KATHLEEN GRACE GAMUTAN, MD
MA. GEMMA DATU-FULGADO, MD
MA. LINDA QUEVEDO, MD
PAULA CRISTO TOLENTINO-ORLINA, MD
PAULINE ANTONETTE REYES, MD
WENDY NICANOR, MD
Committee Chair:
Carmela Madrigal-Dy, MD
VISION
Promote the continuing education of trainers and members in advanced obstetric ultrasound
MISSION
- Conduct didactics and hands-on sessions on advanced obstetric ultrasound for the trainers of the accredited fellowship training hospitals.
- Encourage the participation of the members in the workshops and certification courses on advanced obstetric ultrasound.
- Sustain the knowledge and skills on advanced obstetric ultrasound through regular refresher courses and certification courses.
- Invite foreign experts to conduct hands-on workshops in advanced obstetric ultrasound
Fetal Growth Restriction
SHIERLY MAY DEL ROSARIO, MD
LINDA LUISA YANDOC, MD
GAYLINEL BONGYAD-SAN PEDRO, MD
VICAR ONG, MD
KRISTINA DOSDOS, MD
RIOFERIO GLADIES, MD
AILEEN ONA-SUGUITAN, MD
KRISTINE SESE, MD
ALEJANDRA KAREN TOLEDO, MD
MA. THERESA MULDONG, MD
MARIE CATHELEEN SANTIAGO, MD
MARIA LOURDES OTAYZA, MD
GAY BAUTISTA GUIYAB, MD
GEMMA FULGADO, MD
ALPHA MONTAOS, MD
MARIA LOURDES COLOMA, MD
ZARINAH GONZAGA, MD
KATLEEN DEL PRADO, MD
MARIA ROSARIO CHENG, MD
MA. LINDA QUEVEDO, MD
DENNIS JOHN ORTIGA, MD
MARIE CATHELEEN SANTIAGO, MD
NERISSA GRACIA NANO-DE GUZMAN, MD
JOSEPH CARL MACALINTAL, MD
ALPHA MONTAOS, MD
JACEL ROSALES, MD
KATHLEEN GRACE GAMUTAN, MD
LIZZETTE CARO-ALQUIROS, MD
Committee Chair:
Maria Rosario Cheng, MD
VISION
A future where every case of fetal growth restriction is detected early, managed effectively and monitored closely to ensure optimal growth and development ultimately reducing the risks associated with this condition and improving long term outcomes for these babies.
Through innovative research, collaboration with health care professionals and continuous education, we aim to set new standards of care and support for clinicians and families affected by fetal growth restriction, fostering a culture of excellence and empathy in perinatal health management.
MISSION
To ensure the provision of a comprehensive, evidence based and compassionate management strategy for all cases of fetal growth restriction that prioritize the health and wellbeing of both the maternal and fetal dyad with the goal of optimizing outcomes and ensuring the best possible start in life for every neonate.
Fetal Surveillance
CHRISTINE AGUILAR, MD
MARIA LOURDES OTAYZA, MD
MA. SOCORRO ROGELANNIE BRILLANTES, MD
ELIJINESE MARIE CULANGEN, MD
MANBEE GENE GRANADA, MD
WENDY NICANOR, MD
MARIA ELSA AQUINO, MD
ELISA PATRICIA MAY MALVAR-CORNELIO, MD
JOANNA ZERLINE LOZADA-PASCUAL, MD
MARIA LOURDES COLOMA, MD
JOSEPH OLIVAR, MD
KATLEEN DEL PRADO, MD
MARIA LOURDES SOLIDUM, MD
MARIA NIZA REYES, MD
RAMON REYLES, MD
PAULA CHRISTI TOLENTINO-ORLINA, MD
MA. CORAZON DE JESUS, MD
MA. CRESILDA PAZ SABULRCE, MD
MARIA CARMINA SANTIAGO-OCAMPO, MD
Committee Chair:
Ramon T. Reyles, MD
Recurrent Pregnancy Loss
KATHRYN KRISTY BAUSTISTA, MD
MARIA CARMINA SANTIAGO-OCAMPO, MD
JULIETA VILLANUEVA, MD
ANA MARIE MADAMBA-BURGOS, MD
ZARAH CHARISSA MAGNAYE-AGUALADA, MD
CATHERINE HUI TIIN LIM, MD
CRISTINE FERNANDEZ TANTOCO, MD
MARIA LOURDES OTAYZA, MD
MAYNILA DOMINGO, MD
EDELIZA ELVAMBUENA-AMORIN, MD
GAY BAUTISTA GUIYAB, MD
JOANNA ZERLINE LOZADA-PASCUAL, MD
KAREN TY-TORREDES, MD
ANNE VICTORIA MENDOZA, MD
JACEL ROSALES, MD
MARIA ELSA AQUINO, MD
ELISA PATRICIA MAY MALVAR-CORNELIO, MD
MARIA CZARINA MENDOZA, MD
WALFRIDO SUMPAICO, MD
MARIA NIZA REYES, MD
VALERIE GUINTO, MD
YVONNE JOIE PALMA, MD
MICHELLE MARTIN-BELANDRES, MD
SHARON JANE GALAGNARA, MD
ANA SY, MD
CATHERINE BARBOSA-MACARAIG, MD
CECILE STA. ANA, MD
GAYLINEL BONGYAD-SAN PEDRO
MA. SOCORRO ROGELAINE BRILLIANTES, MD
MA. THERESA MULDONG, MD
JOANNA PAULINE URSUA, MD
VICAR ONG, MD
MAUREEN DIMAMAY-DAZO, MD
CHRISTINE ARCALA-ALEGARBES, MD
LIZZETTE CARO-ALQUIROS, MD
Committee Chair:
Valerie Guinto, MD
Diabetes Mellitus and Obesity
SHIERLY MAY DEL ROSARIO, MD
PAULA TOLENTINO-ORLINA, MD
CARMEN ADELA PEREZ, MD
MA. LINDA QUEVEDO, MD
ALEJANDRA KAREN TOLEDO, MD
CATHERINE BARBOSA-MACARAIG, MD
MARIA YSABEL LUCIA AGCAOILI, MD
ELIJINESE MARIE CULANGEN, MD
AMARYLLIS DIGNA YAZON, MD
JAY VEE LYNE IÑIGO, MD
EBBY EUNIKA REBUGIO, MD
BRENAN IAN CAPUNO, MD
MAY HIPOLITO, MD
LINDA LUISA YANDOC, MD
MILA IBAY, MD
MARIA LOURDES SOLIDUM, MD
GAZELLE MARILAG BAYSA-PEE, MD
VALERIE GUINTO, MD
MA. CORAZON DE JESUS, MD
TERESITA ORTIN OLIVER, MD
MARIA CATHLEEN SANTIAGO, MD
PAULINE ANTONETTE REYES, MD
VANESSA MARIE LIM, MD
Committee Chair:
Maria Lourdes Solidum, MD
VISION
To be a global leader in advancing maternal and fetal health outcomes in women with diabetes, through evidence-based research, education, and advocacy.
MISSION
- Promote optimal maternal and fetal health: By providing guidelines, education, and support for healthcare professionals managing pregnant women with diabetes.
- Advance research: To drive innovation and improve understanding of the pathophysiology, prevention, and treatment of diabetes-related complications in pregnancy.
- Advocate for patient-centered care: By ensuring that pregnant women with diabetes have access to high-quality, culturally appropriate care.
- Foster collaboration: By building partnerships with other healthcare professionals, researchers, and patient advocacy groups to address the unique challenges faced by pregnant women with diabetes.
Autoimmune Disorder
KATHRYN KRISTY BAUTISTA, MD
ANA MARIE MADAMBA-BURGOS, MD
AILEEN ONA-SUGUITAN, MD
ELIJINESE MARIE CULANGEN, MD
MARIA CZARINA MENDOZA, MD
GAZELLE MARILAG BAYSA-PEE, MD
MARLIZ QIANZON-ESCAÑO, MD
MICHELLE MARTIN-BELANDRES, MD
JEMIMAH CARTAGENA-LIM
EMICEL ALTA GIGANTE, MD
SHARON JANE GALAGNARA, MD
CARMEN ADELA PEREZ, MD
MA. LINDA QUEVEDO, MD
MARIA CARMINA SANTIAGO-OCAMPO, MD
ZARAH CHARISSA MAGNAYE-AGUALADA, MD
Committee Chair:
Maria Czarina Mendoza, MD
VISION
To enhance the society’s mastery of Autoimmune Disorders in pregnancy by 2026
MISSION
- To provide a forum for MFM members to network and explore matters on Autoimmune Disorders in Pregnancy
- To develop training and educational resources and clinical practice guidelines related to Autoimmune Disorders in Pregnancy
- To develop collaborative clinical or research projects related to Autoimmune Disorders in Pregnancy
- To promote advocacy and to develop policy position statements related to Autoimmune Disorders in Pregnancy
- To promote awareness of current issues relating Autoimmune Disorders in Pregnancy
- To provide pool of speakers for postgraduate course, congress, and other scientific activities
Fetal Therapy
TRINILISA BAGALSO, MD
MA CRESILDA PAZ SABULARCE, MD
ANA SY, MD
JOSEPH CARL MACALINTAL, MD
MARIA CARMINA SANTIAGO-OCAMPO, MD
GAYLINEL BONGYAD-SAN PEDRO, MD
JULIETA VILLANUEVA, MD
MA. LINDA QUEVEDO, MD
KRISTINA DOSDOS, MD
MARLIZ ESCAÑO, MD
GLADIES, MD
JOSEPHINE SANCHEZ, MD
JOCELYN CENIZAL-BAMBALAN, MD
CHRISTINE AGUILAR, MD
PAULINE ANTONETTE REYES, MD
CRISTINE FERNANDEZ TANTOCO, MD
MA. SOCORRO ROGELANNIE BRILLANTES, MD
JOANNA PAULINE URSUA, MD
EDELIZA ELVAMBUENA-AMORIN, MD
GAY BAUTISTA GUIYAB, MD
KAREN TY-TORREDES, MD
ANNE VICTORIA MENDOZA, MD
JACEL ROSALES, MD
BRENAN IAN CAPUNO, MD
AURORA VICTORIA AVELINO, MD
MA. CRISTINA CRISOLOGO, MD
ZARINAH GONZAGA, MD
MARIA ROSARIO CHENG, MD
BERLY BALITA, MD
MAYCHIEL PEREZ, MD
CLARISSA VELAYO, MD
RAMON REYLES, MD
LEAH SOCORRO RIVERA, MD
NERISSA GRACIA NANO-DE GUZMAN, MD
JEMIMAH CARTAGENA-LIM
VALERIE GUINTO, MD
MA. CORAZON DE JESUS, MD
EMICEL ALTA GIGANTE, MD
TERESITA ORTIN OLIVER, MD
AMARYLLIS DIGNA YAZON, MD
ELIJINESE MARIE CULANGEN, MD
MA. SOCORRO ROGELAINE BRILLIANTES, MD
MA. THERESA MULDONG, MD
Committee Chair:
Karen Alessandra Ty-Torredes, MD
VISION
- To provide equal opportunities for patients to receive fetal therapy in the country
- To improve fetal therapy locally by promoting education and research
MISSION
- To ensure high-quality fetal therapy is available to all Filipinos
- To enhance PSMFM member competency by supporting advanced training in fetal therapy
Electronic Fetal Monitoring
EMERSON TAN, MD
LINDA LUISA YANDOC, MD
VANESSA MARIE LIM, MD
CECILE STA. ANA, MD
MA. SOCORRO ROGELANNIE BRILLANTES, MD
JOANNA ZERLINE LOZADA-PASCUAL, MD
MANBEE GENE GRANADA, MD
RAMON REYLES, MD
LEAH SOCORRO RIVERA, MD
GUMERSINDA JAVIER, MD
VALERIE GUINTO, MD
MARIA ESTRELLA FLORES, MD
CARMELA MADRIGAL-DY, MD
MARJORIE SANTOS, MD
RICHARD JORDIAS, MD
LUCIA TIANGCO, MD
IRENE QUINIO, MD
CATHERINE JOIE CARELLE ONG, MD
SHERRI ANN SUPLIDO, MD
CATHERINE HUI TIIN LIM, MD
EBBY EUNIKA REBUGIO, MD
GLADIES RIOFERIO, MD
Committee Chair:
Maria Estrella Flores, MD
VISION
To play a pivotal role in ensuring that the interpretation of electronic fetal monitoring aligns with the utmost standards of care in perinatal medicine.
MISSION
To establish a unified approach to the interpretation of electronic fetal monitoring by promoting interdisciplinary cooperation among healthcare professionals through ongoing education, and advocating for evidence-based practices to enhance perinatal outcomes.
Perinatal Epidemiology
JOANNA ZERLINE LOZADA-PASCUAL, MD
AMARYLLIS DIGNA YAZON, MD
MARIO PHILIP FESTIN, MD
VALERIE GUINTO, MD
TERESITA ORTIN OLIVER, MD
SHARON JANE GALAGNARA, MD
MA. CRISTINA CRISOLOGO, MD
IRENE QUINIO, MD
LORA GARCIA-TANSENGCO, MD
MARIA GERALDINE ASSUMPTION GAVINA C. TORRALBA, MD
JOANNA ZERLINE LOZADA-PASCUAL, MD
MARIA ELSA AQUINO, MD
Committee Chair:
Mario Philip Festin, MD
VISION
To have healthy and happy mothers during pregnancy, who have access to the best health care, and having safe deliveries of healthy babies
MISSION
By monitoring the indicators of perinatal health care, and using the best evidence, we shall ensure that all providers of maternal and perinatal care, and all services meet the highest quality standards, at all times.